Castel S.A. v. Christopher A. Wilson

CourtDistrict Court, C.D. California
DecidedJuly 15, 2020
Docket2:19-cv-09336
StatusUnknown

This text of Castel S.A. v. Christopher A. Wilson (Castel S.A. v. Christopher A. Wilson) is published on Counsel Stack Legal Research, covering District Court, C.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Castel S.A. v. Christopher A. Wilson, (C.D. Cal. 2020).

Opinion

O 1

2 3 4 5 6 7 8 United States District Court 9 Central District of California 10 11 CASTEL S.A., a Luxembourg joint stock Case No.: 2:19-cv-09336-ODW-(MAAx) company (societe anonyme), 12 Plaintiff, 13 ORDER GRANTING IN PART AND v. DENYING IN PART DEFENDANTS’ 14 MOTIONS TO DISMISS [46, 47, 48, 49] 15 CHRISTOPHER A. WILSON, an individual; PHAROS CAPITAL 16 PARTNERS II, LP, a Delaware limited 17 partnership; PHAROS CAPITAL PARTNERS II-A, LP, a Delaware limited 18 partnership; OLIVIA HO CHENG, an 19 individual; ARF PARTNERS, LLC, a 20 Massachusetts corporation; AURORA HEALTHCARE US CORP, a 21 Massachusetts corporation; STEVEN J. 22 JAMES, an individual. 23 Defendants. 24 I. INTRODUCTION 25 Before the Court are four motions: 26 1. A Motion to Dismiss under Federal Rule of Civil Procedure (“Rule”) 27 12(b)(6) filed by defendant Christopher Wilson (“Wilson”). (See Wilson Mot. to 28 Dismiss (“Wilson Mot.”), ECF No. 46.) 1 2. A Motion to Dismiss under Rules 12(b)(2), 12(b)(6), and 9(b) filed by 2 defendants Pharos Capital Partners II, LP, and Pharos Capital Partners II-A, LP 3 (collectively, “Pharos”). (See Pharos Mot. to Dismiss (“Pharos Mot.”), ECF No. 47.) 4 3. A Motion to Dismiss under Rule 12(b)(6) filed by defendants Olivia Ho 5 Cheng (“Cheng”) and ARF Partners, LLC (“ARF”) (collectively, the “ARF 6 Defendants”). (See ARF Mot. to Dismiss (“ARF Mot.”), ECF No. 48.) 7 4. A Motion to Dismiss under Rules 12(b)(6) and 12(b)(2) filed by 8 defendants Aurora Healthcare US Corp. (“Aurora”) and Steven James (“James”) 9 (collectively, the “Aurora Defendants”). (See Aurora Mot. to Dismiss (“Aurora 10 Mot.”), ECF No. 49.) 11 Defendants’ motions have been fully briefed. For the following reasons, the 12 Court GRANTS IN PART and DENIES IN PART Defendants’ motions.1 13 II. PLAINTIFF’S ALLEGATIONS 14 Plaintiff Castel S.A., a Luxembourg joint stock company (societe anonyme) 15 (“Plaintiff”) filed its First Amended Complaint (“FAC”) on January 29, 2020, alleging 16 eight causes of action against seven defendants. (See FAC, ECF No. 44.) The FAC 17 describes the insolvency and sale of Aurora Imaging Technology, Inc. (“AIT”), a 18 company with a California principal place of business that developed, manufactured, 19 and sold a system used to perform breast MRIs. (FAC ¶¶ 21, 31–39.) 20 Plaintiff first invested in AIT on June 19, 2006, purchasing 1,010,101 shares of 21 AIT’s Series C preferred stock in accordance with the Series C Preferred Stock 22 Purchase Agreement between Plaintiff and AIT.2 (FAC ¶ 23.) Plaintiff again invested 23 in AIT on July 15, 2008, purchasing 512,821 shares of AIT’s Series D preferred stock 24 in accordance with the Series D Preferred Stock Purchase Agreement.3 (FAC ¶ 24.) 25 Plaintiff therefore owned almost 4% of AIT and was at all relevant times a minority 26

1 After carefully considering the papers filed in connection with the motions, the Court deemed this 27 matter appropriate for decision without oral argument. Fed. R. Civ. P. 78(b); C.D. Cal. L.R. 7-15. 28 2 The Series C Preferred Stock Purchase Agreement is Exhibit A to the FAC. (ECF No. 44-1.) 3 The Series D Preferred Stock Purchase Agreement is Exhibit B to the FAC. (ECF No. 44-2.) 1 shareholder of AIT. (FAC ¶ 25.) In addition to stock, Plaintiff lent $250,000 to AIT 2 on March 14, 2011, documented by a promissory note. (FAC ¶ 26.) Pharos owned 3 83.3% of the Series C and Series D Preferred Stock of AIT and held $3,300,000 in 4 senior secured promissory notes in AIT. (FAC ¶ 27.) 5 Cheng was the President and CEO of AIT from 2002 to 2012, but was 6 “basically forced to resign” by AIT’s Board of Directors in 2012. (FAC ¶¶ 76–77.) 7 Cheng owned 185,814 shares of Series A preferred stock, 66,750 shares of Series B 8 preferred stock, and 264,697 shares of Common Stock of AIT. (FAC ¶ 78.) Cheng is 9 also the owner and manager of ARF, a Massachusetts limited liability company that 10 purchased Pharos’s notes and investments in AIT as described below. (FAC ¶ 79.) 11 By mid-2015, AIT was over $20,000,000 in debt and insolvent. (FAC Ex. H 4- 12 5, ECF No. 44-8.) Around that time, AIT hired Wilson as its CEO to guide it through 13 bankruptcy. (FAC ¶¶ 53–55.) “At all relevant times,” Wilson owned 17,811 shares of 14 common stock, 13,122 shares of Series A preferred stock, and 625 shares of Series B 15 preferred stock of AIT. (FAC ¶ 56.) 16 On November 25, 2015, Pharos entered into a Stock and Note Purchase 17 Agreement4 under which Cheng, through ARF, purchased Pharos’s secured notes and 18 shares of AIT for $450,000. (FAC ¶¶ 28, 79, 82–83.) This transaction was approved 19 by Wilson as CEO of AIT. (FAC ¶ 58.) Cheng thereafter began negotiations to 20 purchase AIT’s assets through Aurora Healthcare SPC, of which Cheng was the 21 manager and CEO. (FAC ¶¶ 31–33, 39.) 22 On October 20, 2016, Wilson informed Plaintiff that AIT “received only one 23 offer to purchase the assets of the business for $8,500,000, which we are going to 24 accept, subject to the approval of the shareholders.” (See FAC Ex. H, ECF No. 44-7.) 25 Wilson also wrote that the purchase price was insufficient to pay AIT’s existing debts, 26 and the sale’s proceeds would therefore be “distributed pro rata to all debtors, subject 27 to their signing a settlement agreement and mutual release.” (FAC Ex. H.) Plaintiff 28 4 The Stock and Note Purchase Agreement is Exhibit D to the FAC. (ECF No. 44-4.) 1 objected to the sale, stating that it did not have sufficient information to make an 2 informed decision and that it was entitled to receive all material information 3 concerning the proposed sale. (See FAC Ex. G, ECF No. 44-8.) Wilson responded 4 that “I am happy to provide any information you want to receive” and attached AIT’s 5 financial statements for the previous five years showing more liabilities than assets, 6 including over $12,000,000 in past due loans. (See FAC Ex. G.) Wilson continued: 7 “The current owner of the senior secured debt originally issued to Pharos could have 8 acquired all of the assets of the company by commencing legal proceedings, which 9 would have left nothing for any of the unsecured creditors. While the current offer is 10 less than we hoped, it is the only offer we have that returns any amounts to the 11 unsecured creditors. If you have specific information you would like to see, please let 12 me know. We can also make all of the company records available to you at the 13 company offices in Danvers, Massachusetts.” (FAC Ex. G.) Plaintiff objected again, 14 stating that Wilson’s communications did not constitute all material information 15 concerning the proposed sale, and that those communications were “inaccurate or 16 misleading.” (See FAC Ex. G.) 17 Despite Plaintiff’s objections, Aurora Healthcare SPC and AIT executed the 18 Asset Purchase Agreement5 on October 31, 2016 in which Aurora Healthcare SPC 19 agreed to purchase AIT’s assets for $8,500,000. (FAC ¶ 37.) The purchase price 20 consisted of $4,300,000 in secured debt originally held by Pharos and $4,200,000 in 21 cash. (See Asset Purchase Agreement § 3, ECF No. 44-9.) The Asset Purchase 22 Agreement stated that the $4,300,000 in secured debt “would otherwise be due and 23 payable to Buyer, as the holder of the senior secured debt of [s]eller to Pharos Capital 24 Partners, L.P. and its affiliates.” (Asset Purchase Agreement § 3.1.) 25 Upon Plaintiff’s information and belief, the Asset Purchase Agreement allowed 26 Cheng to purchase Pharos’s notes for “pennies on the dollar,” and then receive 27 $4,300,000 through Aurora Healthcare SPC at Plaintiff’s expense. (FAC ¶ 39.) 28 5 The Asset Purchase Agreement is Exhibit I to the FAC. (ECF No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Santana v. Calderon
342 F.3d 18 (First Circuit, 2003)
D. Neubronner v. Michael R. Milken
6 F.3d 666 (Ninth Circuit, 1993)
Dole Food Company, Inc. v. Watts
303 F.3d 1104 (Ninth Circuit, 2002)
Marder v. Lopez
450 F.3d 445 (Ninth Circuit, 2006)
Gary Davis v. Hsbc Bank Nevada, N.A.
691 F.3d 1152 (Ninth Circuit, 2012)
AREI II Cases
216 Cal. App. 4th 1004 (California Court of Appeal, 2013)
Menken v. Emm
503 F.3d 1050 (Ninth Circuit, 2007)
Applied Equipment Corp. v. Litton Saudi Arabia Ltd.
869 P.2d 454 (California Supreme Court, 1994)
Lazy Y Ranch Ltd. v. Behrens
546 F.3d 580 (Ninth Circuit, 2008)
Boschetto v. Hansing
539 F.3d 1011 (Ninth Circuit, 2008)
Feldman v. Cutaia
951 A.2d 727 (Supreme Court of Delaware, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
Castel S.A. v. Christopher A. Wilson, Counsel Stack Legal Research, https://law.counselstack.com/opinion/castel-sa-v-christopher-a-wilson-cacd-2020.